Τίτλος:
Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Arterial stiffness is linked to the progression of atherosclerosis, while activation of vitamin D receptor exerts favorable cardiovascular effects in patients with renal insufficiency. In this study, we investigated the effects of oral treatment with paricalcitol, a potent vitamin D receptor activator, on arterial stiffness and osteopontin, a marker of atherosclerosis, in hypertensive patients with chronic kidney disease (CKD) and secondary hyperparathyroidism. Methods: We followed up 29 treated hypertensive patients (mean age: 74.1 years, 19 men, office blood pressure = 132/85 mmHg) with CKD stages 3–5 (mean glomerular filtration rate [GFR] = 19.4 ml/min/1.73 m2) who were on therapy with oral paricalcitol for 1 year. The control group consisted of 10 age-, sex-, and GFR-matched hypertensive patients with secondary hyperparathyroidism. Results: After 1 year of treatment with paricalcitol compared to baseline, there was no statistical difference in levels of GFR, office blood pressure, and osteopontin (p = NS for all), while carotid-femoral PWV was reduced from 11.8 ± 2.6 m/s to 11.2 ± 2.4 m/s (p < 0.05). The control group exhibited no significant changes in carotid-femoral PWV (p = NS). Conclusions: Treatment with oral paricalcitol in hypertensive subjects suffering from CKD stages 3–5 and secondary hyperparathyroidism is accompanied by amelioration of arterial stiffness as reflected by the reduction of carotid-femoral PWV. © 2018 Hellenic Society of Cardiology
Συγγραφείς:
Giakoumis, M.
Tsioufis, C.
Dimitriadis, K.
Sonikian, M.
Kasiakogias, A.
Andrikou, E.
Kalos, T.
Konstantinidis, D.
Filis, K.
Petras, D.
Tousoulis, D.
Περιοδικό:
Ελληνική καρδιολογική επιθεώρηση
Εκδότης:
Hellenic Cardiological Society
Λέξεις-κλειδιά:
25 hydroxyvitamin D; C reactive protein; creatinine; hemoglobin A1c; high density lipoprotein cholesterol; low density lipoprotein cholesterol; magnesium; osteopontin; parathyroid hormone; paricalcitol; triacylglycerol; uric acid; bone density conservation agent; calcitriol receptor; ergocalciferol; osteopontin; paricalcitol; VDR protein, human, aged; arterial stiffness; Article; blood pressure; blood sampling; chronic kidney failure; clinical article; controlled study; diabetes mellitus; drug effect; drug exposure; enzyme linked immunosorbent assay; female; follow up; glomerulus filtration rate; human; hyperlipidemia; hypertensive patient; ischemic heart disease; kidney function; male; renin angiotensin aldosterone system; secondary hyperparathyroidism; arterial stiffness; atherosclerosis; chronic kidney failure; comparative study; complication; drug effect; hypertension; metabolism; middle aged; oral drug administration; pathophysiology; physiology; secondary hyperparathyroidism; very elderly, Administration, Oral; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Bone Density Conservation Agents; Carotid-Femoral Pulse Wave Velocity; Ergocalciferols; Female; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Hypertension; Male; Middle Aged; Osteopontin; Receptors, Calcitriol; Renal Insufficiency, Chronic; Vascular Stiffness
DOI:
10.1016/j.hjc.2017.12.010
